Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy
Naoto Nishii, Hidetake Tachinami, Yuta Kondo, et al.
Oncotarget (2018) Vol. 9, Iss. 17, pp. 13301-13312
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Trial watch: TLR3 agonists in cancer therapy
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 225
Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
Baharak Bahmani, Hua Gong, Brian T. Luk, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 222
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Sachin Bhagchandani, Jeremiah A. Johnson, Darrell J. Irvine
Advanced Drug Delivery Reviews (2021) Vol. 175, pp. 113803-113803
Open Access | Times Cited: 126
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
Christian Rolfo, Elisa Giovannetti, Pablo Martínez, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 86
The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
Hajar Alemohammad, Basira Najafzadeh, Zahra Asadzadeh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112516-112516
Open Access | Times Cited: 70
Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
Samik Chakraborty, Juan Ye, Herui Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 39
Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs
Gregory M. Cresswell, Bingbing Wang, Erin M. Kischuk, et al.
Cancer Research (2020) Vol. 81, Iss. 3, pp. 671-684
Open Access | Times Cited: 51
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yu Yuan, Abdalla Adam, Chen Zhao, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 663-663
Open Access | Times Cited: 50
Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine
Hyunjoon Kim, Thomas S. Griffith, Jayanth Panyam
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 370, Iss. 3, pp. 715-724
Open Access | Times Cited: 43
Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
Miaoqin Chen, Shiman Hu, Yiling Li, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 34
Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
Leila Rostamizadeh, Ommoleila Molavi, Mohsen Rashid, et al.
Bioimpacts (2022)
Open Access | Times Cited: 19
Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapy
Esben Christensen, Camilla Stavnsbjerg, Rasmus Münter, et al.
The Journal of Immunology (2025)
Open Access
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine
Hyunjoon Kim, Vidhi Khanna, Tamara A. Kucaba, et al.
Molecular Pharmaceutics (2019) Vol. 16, Iss. 3, pp. 1200-1210
Closed Access | Times Cited: 35
Toll-Like Receptors as a New Era in Cancer Therapy
Mohammed AW. Almorish, Ali Alyahawi
IntechOpen eBooks (2025)
Open Access
Endogenous IL-33 exerts CD8+ T cell antitumor responses overcoming pro-tumor effects by regulatory T cells in a colon carcinoma model
Yulong Xia, Tatsukuni Ohno, Naoto Nishii, et al.
Biochemical and Biophysical Research Communications (2019) Vol. 518, Iss. 2, pp. 331-336
Closed Access | Times Cited: 24
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Chuanhui Han, Anli Zhang, Zhida Liu, et al.
Oncogene (2020) Vol. 40, Iss. 5, pp. 885-898
Closed Access | Times Cited: 18
Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
Neftali Ortega Alarcon, Maddy Jaramillo, Heidi M. Mansour, et al.
Pharmaceutics (2022) Vol. 14, Iss. 7, pp. 1448-1448
Open Access | Times Cited: 10
Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism
Austin T. Ryan, Anunay James Pulukuri, Maryam Davaritouchaee, et al.
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 7, pp. 995-1004
Open Access | Times Cited: 13
Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis
Zhou Tian, Baojian Hong, Jianzhong Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Immunostimulatory TLR7 Agonist‐Nanoparticles Together with Checkpoint Blockade for Effective Cancer Immunotherapy
Ching‐Hsin Huang, Natalie Mendez, Oscar Echeagaray, et al.
Advanced Therapeutics (2020) Vol. 3, Iss. 6
Open Access | Times Cited: 11
Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade
Hidetake Tachinami, Naoto Nishii, Yulong Xia, et al.
Oral Oncology (2019) Vol. 91, pp. 21-28
Closed Access | Times Cited: 9
A TLR7 agonist activates bovine Th1 response and exerts antiviral activity against bovine leukemia virus
Yamato Sajiki, Satoru Konnai, Tomohiro Okagawa, et al.
Developmental & Comparative Immunology (2020) Vol. 114, pp. 103847-103847
Open Access | Times Cited: 9
Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
Marjan Azin, Kenneth Ngo, Jennet Hojanazarova, et al.
JID Innovations (2023) Vol. 3, Iss. 6, pp. 100221-100221
Open Access | Times Cited: 3
In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds
Dirk Theile, Lelia Wagner, Walter E. Haefeli, et al.
European Journal of Pharmaceutical Sciences (2021) Vol. 162, pp. 105826-105826
Closed Access | Times Cited: 6
Orthotopic tongue squamous cell carcinoma (SCC) model exhibiting a different tumor-infiltrating T-cell status with margin-restricted CD8+ T cells and regulatory T cell-dominance, compared to skin SCC
Yoshihisa Kashima, Naoto Nishii, Hidetake Tachinami, et al.
Biochemical and Biophysical Research Communications (2020) Vol. 526, Iss. 1, pp. 218-224
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top